Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30722039 | 1.00 | GAA (0.47) | GAATDP1TSHRSMN1; SMN2KMT2A | |
| SCHEMBL28660776 | 0.76 | POLB (0.41) | GAAKMT2AALDH1A1SIGMAR1 | |
| SCHEMBL4816836 | 0.75 | GPR35 (0.35) | GAATDP1TSHRSMN1; SMN2KMT2A | |
| SCHEMBL1715556 | 0.72 | GAA (0.42) | GAATDP1TSHRSMN1; SMN2KMT2A | |
| SCHEMBL7969057 | 0.72 | ALDH1A1 (0.35) | GAATSHRSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL23346795 | 0.70 | ADRA2C (0.39) | GAATDP1TSHRKMT2AHTT | |
| SCHEMBL30722035 | 0.70 | ADRA2C (0.39) | GAATDP1TSHRKMT2AHTT | |
| SCHEMBL11817643 | 0.69 | TDP1 (0.45) | GAATDP1TSHRSMN1; SMN2KMT2A | |
| Iodide SCHEMBL29271507 | 0.69 | ADRA2C (0.38) | GAATSHRKMT2AHTTLMNA | |
| SCHEMBL2478764 | 0.69 | GAA (0.48) | GAATDP1TSHRSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102600488-B | IMAGING THE CENTRAL NERVOUS SYSTEM | GE HEALTHCARE LTD | 2013-11-20 | — | — | CN | disclosed |
| CN-102600487-B | Imaging the central nervous system | GE HEALTHCARE LTD | 2013-11-20 | — | — | CN | disclosed |
| EP-2247316-B1 | IMAGING THE CENTRAL NERVOUS SYSTEM | GE HEALTHCARE LTD (GB) | 2013-11-06 | — | — | EP | disclosed |
| CN-102600487-A | Imaging the central nervous system | GE HEALTHCARE LTD | 2012-07-25 | — | — | CN | disclosed |
| CN-102600488-A | IMAGING THE CENTRAL NERVOUS SYSTEM | GE HEALTHCARE LTD | 2012-07-25 | — | — | CN | disclosed |
| CN-101970017-B | Visualization of the central nervous system | GE HEALTHCARE LTD | 2012-05-23 | — | — | CN | disclosed |
| EP-1685112-B1 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES AS VR1 ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| CN-101970017-A | Visualization of the central nervous system | GE HEALTHCARE LTD | 2011-02-09 | — | — | CN | disclosed |
| US-20110027178-A1 | IMAGING THE CENTRAL NERVOUS SYSTEM | GE HEALTHCARE LIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| EP-2247316-A2 | IMAGING THE CENTRAL NERVOUS SYSTEM | GE Healthcare Limited (GB) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106564-A2 | IMAGING THE CENTRAL NERVOUS SYSTEM | GE HEALTHCARE LIMITED (GB) | 2009-09-03 | — | — | WO | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | GAA 2904/4885TDP1 4383/4885TSHR 395/4885 |
| US-20110027178-A1 | IMAGING THE CENTRAL NERVOUS SYSTEM | P2RX3, P2RX7, P2RX2 | GAA 2978/4885TDP1 1403/4885TSHR 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.